PPHM AND MEMORIAL SLOAN KETTERING TO LAUNCH CANCER COLLABORATION

After some months of little news, Peregrine Pharmaceuticals(PPHM) announced a collaboration with Memorial Sloan Kettering to collaborate on cancer research.

They will explore cancer-fighting treatments that combine PPHM's PS targeting agents - including its lead drug candidate, Bavituximab - with other checkpoint inhibitors or immune stimulating agents.

Note the comment by MSK:

"This collaboration will allow us to focus on the role and contribution of PS blockade therapy in determining which combination of the current and next generation of immune modulators is likely to increase the extent and amplitude of anti-tumour response," Taha Merghoub, Ph.D., associate attending biologist with MSK's melanoma and immunotherapeutics service, Ludwig Collaborative and Swim Across America laboratories, said in a statement.

"This important preclinical and translational work will potentially guide the design of the next generation of clinical studies with Bavituximab," added Dr Merghoub, who will direct the collaboration's studies in MSK.

I view this as extremely positive as MSK is a reputed cancer research centre with a proud history. I can only see this as potentially opening more doors to combine bavituximab and PS-targeting agents with various form of cancer treatments, including immunotherapy.

Learn more about MSK here:

https://mskcc.org/about

And more about the news here:

http://www.genengnews.com/gen-news-highlights/peregrine-memorial-sloan-kettering-launch-cancer-collaboration/81251330/

My disclosure: I am long PPHM.